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Introduction: Anti-Jo-1 and anti-Ro52 autoantibodies are common in patients with myositis, but the mechanisms
behind their production are not known. Survival of autoantibody-producing cells is dependent on B-cell-activating
factor of the tumour necrosis factor family (BAFF). BAFF levels are elevated in serum of anti-Jo-1-positive
myositis patients and are influenced by type-I interferon (IFN). IFN-producing cells and BAFF mRNA expression are
present in myositis muscle. We investigated expression of the receptors for BAFF in muscle tissue in relation to
anti-Jo-1 and anti-Ro52/anti-Ro60 autoantibodies and type-I IFN markers.
Methods: Muscle biopsies from 23 patients with myositis selected based on autoantibody profile and 7 healthy
controls were investigated for expression of BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA) and
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Nineteen samples were
assessed for plasma (CD138) and B-cell (CD19) markers. The numbers of positive cells per area were compared
with the expression of plasmacytoid dendritic cell (pDC) marker blood dendritic cell antigen-2 (BDCA-2) and
IFNα/β-inducible myxovirus resistance-1 protein (MX-1).
Results: BAFF-R, BCMA and TACI were expressed in five, seven and seven patients, respectively, and more
frequently in anti-Jo-1-positive and/or anti-Ro52/anti-Ro60-positive patients compared to controls and to patients
without these autoantibodies (P = BAFF-R: 0.007, BCMA: 0.03 and TACI: 0.07). A local association of receptors with B
and plasma cells was confirmed by confocal microscopy. The numbers of CD138-positive and BCMA-positive cells
were correlated (r = 0.79; P = 0.001). Expression of BDCA-2 correlated with numbers of CD138-positive cells and
marginally with BCMA-positive cells (r = 0.54 and 0.42, respectively; P = 0.04 and 0.06, respectively). There was a
borderline correlation between the numbers of positively stained TACI cells and MX-1 areas (r = 0.38, P = 0.08).
Conclusions: The expression pattern of receptors for BAFF on B and plasma cells in muscle suggests a local role for
BAFF in autoantibody production in muscle tissues of patients with myositis who have anti-Jo-1 or anti-Ro52/anti-Ro60
autoantibodies. BAFF production could be influenced by type-I IFN produced by pDCs. Thus, B-cell-related molecular
pathways may participate in the pathogenesis of myositis in this subset of patients.* Correspondence: krystufkova@revma.cz
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Idiopathic inflammatory myopathies (IIMs), collectively
named myositis, are characterised by muscle weakness
and inflammation in skeletal muscle tissue. On the basis
of their clinical and histopathological features, they may
be subclassified into polymyositis (PM), dermatomyositis
(DM), immune-mediated necrotising myopathy (IMNM)
and inclusion body myositis (IBM). Autoantibodies are
frequently found in PM, DM and IMNM, but less often
in IBM. Of these, the so-called myositis-specific auto-
antibodies are closely associated with distinct clinical
phenotypes [1]. The most common myositis-specific
autoantibodies are the anti-histidyl-tRNA synthetase
(anti-Jo-1) autoantibodies, which are present in approxi-
mately 10% to 30% of patients with PM and DM [2].
Another subset of autoantibodies is composed of the
so-called myositis-associated autoantibodies, of which
the anti-Ro52 autoantibodies are the most frequent, be-
ing present in 12% to 30% of patients with myositis [3].
These two autoantibodies often co-occur [3,4]. The pro-
duction site of these autoantibodies is not clear, but B-
cell infiltrates and plasma cells have been found in
muscle tissue from patients with IIM [5-9] with the
presence of clonally related B cells and plasma cells [10]
as well as evidence of local affinity maturation [11],
which may indicate local autoantibody production in
the muscle tissue.
An important factor for B-cell maturation is B-cell-
activating factor of the tumour necrosis factor family
(BAFF, also known as BLyS) [12]. Elevated serum levels of
BAFF have been found in subsets of patients with PM and
anti-Jo-1 autoantibodies and in patients with DM [13].
Moreover, serum levels of BAFF correlated positively to
serum levels of creatine phosphokinase and negatively to
treatment with glucocorticoids, which might indicate that
BAFF could have a role in the disease mechanism in sub-
sets of patients with myositis.
BAFF acts through three receptors: BAFF receptor
(BAFF-R), B-cell maturation antigen (BCMA) and trans-
membrane activator and calcium modulator and cyclophi-
lin ligand interactor (TACI). The expression of receptors
differs in various stages of B-cell maturation [14,15]. The
key receptor for maturation of naïve B cells is BAFF-R,
which is expressed by all stages but downregulated during
plasma cell differentiation. BCMA is important for the de-
velopment of mature B cells, is upregulated during differ-
entiation to immunoglobulin (Ig)-secreting cells and
supports the survival of long-lived plasma cells in bone
marrow [16]. TACI is expressed on activated B cells dur-
ing differentiation towards plasma cells, provides positive
signals to plasmablasts and has a role in isotype switching
[17]. However, TACI also negatively regulates clonal ex-
pansion of B cells by mechanisms of activation-induced
cell death [18], and it could also reduce the availability ofBAFF for BAFF-R; hence, TACI has indirect control of
BAFF levels [19].
The production of BAFF is induced by type I interferons
(IFN-α/β) [20]. In addition, upon IFN-α/β exposure, B
cells can differentiate into plasmablasts and increase their
resistance to Fas-mediated apoptosis and promote survival
[21,22]. The cellular source of type I IFNs, the plasma-
cytoid dendritic cells (pDCs), together with the IFNα/β-
inducible myxovirus resistance 1 (MX-1) protein, has
been demonstrated in muscle tissue of patients with
PM, DM and IBM [23,24]. Sera from patients with
myositis or systemic lupus erythematosus who have
anti-Jo-1 and/or anti-Ro52/anti-Ro60 (anti-SSA) auto-
antibodies have IFN-α-inducing property. It has been
suggested that immune complexes containing these
autoantibodies directed against RNA-binding proteins
may act as endogenous IFN-α/β-inducing factors [23].
Together, these observations may imply that BAFF and
type I IFN could interact and play a role in the patho-
physiology of myositis with anti-Jo-1 and/or anti-Ro52/
anti-Ro60 autoantibodies.
The biological significance of BAFF in the pathogen-
esis of systemic rheumatic diseases is supported by the
high serum levels of BAFF, by expression of BAFF and
its receptors in affected organs [25] and by the benefi-
cial effects of neutralisation of BAFF by antibodies
(anti-BAFF, anti-BR3) or soluble receptors (TACI-Ig) in
model systems and in clinical trials (reviewed in [26]).
Blockade of BAFF could also potentially be an alterna-
tive to B-cell depletion (by anti-CD20) in patients with
myositis [27].
Therefore, the significance of BAFF in myositis needs
to be further elucidated. Upregulation of the BAFF
mRNA transcript was recently described in muscle tis-
sue of DM, PM and IBM patients [10,28]. Together
with the expression of BAFF-R in muscle fibres and in-
filtrating inflammatory cells, this indicates a potential
local function of BAFF in muscle tissue [28]. On the
basis of our previous observations of elevated serum
levels of BAFF in patients with anti-Jo-1 antibodies [13]
and the demonstration of IFN-α-inducing capacity of
anti-Jo-1 or anti-Ro52/anti-Ro60-positive sera [23], we
postulate that the BAFF pathway could be of particu-
lar relevance for a subset of myositis patients with
autoantibodies.
The aim of our study was to investigate expression of
BAFF receptors (BAFF-R, BCMA and TACI) in the
muscle tissues of patients with and those without anti-
Jo-1 and/or anti-Ro52/anti-Ro60 autoantibodies, irre-
spective of the diagnosis DM, PM or IBM. Furthermore,
as type I IFNs may induce BAFF production, we aimed
to correlate BAFF-R expression in muscle tissue with
markers of the type I IFN pathway in muscle tissue
samples.
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Patients and controls
Muscle biopsy specimens from 23 patients (16 women
and 7 men) with or without anti-Jo-1 and/or anti-Ro52/
anti-Ro60 autoantibodies according to their medical re-
cords were included in this study. They were followed
regularly at the Rheumatology Unit, Karolinska Univer-
sity Hospital, Stockholm, and fulfilled the diagnostic cri-
teria for definite or probable PM (n =11) or DM (n =6)
[29,30] or sporadic IBM (n =6) [31]. They have been
reported previously [23]. The median duration from
diagnosis until the time of muscle biopsy was 0.5 years
(minumum - maximum range: 0 to 22.5 years), and mean
age (SD) was 56.1 ± 12.3 years. At the time of biopsy, 19 pa-
tients were being treated with immunosuppressive agents,
and the median duration of treatment was 1.6 years (range,
0 to 28.5) (Table 1). Three patients with IBM (patients 10,
17 and 23) (Table 1) formerly diagnosed with PM were
treated before the diagnosis of IBM was made (13.7, 9 and
3.2 years, respectively). Biopsy specimens from seven
healthy individuals (four women and three men; mean age
(SD) =60.7 ± 13.6 years) were included as controls. All
patients and control individuals gave their informed con-
sent to participate, and the local ethics committee at the
Karolinska Hospital Nord, Stockholm, approved the study.
Autoantibody detection
Line blot assays (Inno-Lia ANA update test; Innogenetics,
Ghent, Belgium; and Myositis LIA; IMTEC Immundiag-
nostika, Berlin, Germany) and Western blot assay (anti-
myositis antigen EUROLINE-WB kit; Euroimmun,
Lubeck, Germany) were used to define autoantibody
profiles as previously described [13]. The tests included
specificities of autoantibodies against the following
antigens: Jo-1/HRS, SmB, SmD, ribonucleoprotein (RNP)-
70K, RNP-A, RNP-C, Ro52/SSA, Ro60/SSA, La/SSB,
centromere B, topoisomerase-1/Scl70, ribosomal P anti-
gen, histones, Mi-2, PM-Scl/100, U1-snRNP, Ku72/86,
PL-7 and PL-12. Patients who had negative results for
anti-Jo-1 and anti-Ro52/anti-Ro60 in all three specific
tests were considered not to have these autoantibodies.
Muscle biopsy specimens
Muscle tissue specimens were obtained by using a semi-
open technique while the patients were under local an-
aesthesia [32]. The 7-μm-thick serial cryostat sections
were mounted on gelatin-coated glass slides (Cell-Line
Associates, Newfield, NJ, USA) and fixed in 2% formal-
dehyde as previously described [23]. The serial sections
were stored at −80°C until stained. To reduce the possi-
bility of selection bias, the first and last muscle tissue
sections of a series of specimens were stained with haema-
toxylin and eosin to detect inflammatory cell infiltrates
and to exclude any inconsistencies in the biopsies. Usually,two biopsies were sectioned and similar results were
obtained.
Immunohistochemistry
The staining procedure applied was a peroxidase method
previously described [23], with some modifications, as we
used endogenous peroxidase block (with 1% H2O2 and 2%
NaN3), avidin-biotin (Vector Laboratories, Burlingame,
CA, USA) and 1% normal horse serum in blocking steps.
Phosphate-buffered saline (PBS)-saponin (0.1%) was used
for washing and antibody dilution.
Sections were stained overnight using primary antibodies
towards receptors for BAFF (BAFF-R, clone 265.13.1.9.3.2,
final dilution 1 μg/ml), BCMA (clone 255.4.1.2.1.5, final
dilution 4 μg/ml) and TACI (clone 250.13.1.1.4.3, final
dilution 2 μg/ml), all kindly provided by ZymoGenetics
(Seattle, WA, USA). From 15 of the patients and from 4 of
the controls, muscle tissue was available for staining for B
cells using antibodies to CD19 (clone HD37, 0.6 μg/ml)
and for plasma cells using anti-CD138 (clone M115,
1.8 μg/ml) (both from Dako, Glostrup, Denmark). All
primary antibodies used were mouse anti-human IgG1
monoclonal antibodies. Isotype-matched irrelevant anti-
body (mouse IgG1κ, clone DAK-G01 in 4 μg/ml dilu-
tion; Dako) was used as the control.
Following washing and staining steps (as described
previously [23]) with secondary biotinylated horse anti-
mouse IgG antibodies (Vector Laboratories) diluted
1:320 in PBS-saponin with 1% horse serum, incubation
with avidin-biotin-horseradish peroxidase complex (Vec-
tastain ABC Elite Kit; Vector Laboratories), development
with 3,3′-diaminobenzidine (DAB substrate kit; Vector
Laboratories) and a final counterstaining step with Mayer’s
haematoxylin were performed. Sections from human ton-
sils were used for titration of primary antibodies and as
positive controls for staining of B cells, plasma cells and
receptors for BAFF (Additional file 1: Figure S1). For
expression of pDC marker blood dendritic cell antigen 2
(BDCA-2/CD303) and MX-1 protein, we used already
stained slides where consecutive serial sections were
available from the same patients (n =23) [23].
Evaluation of immunohistochemical staining
Entire tissue sections were analysed using a conventional
microscope (Reichert-Jung Polyvar 2; Leica, Vienna,
Austria) in a coded manner by three independent asses-
sors. The mean numbers of cells positive for receptors
for BAFF, CD19 and CD138 per square millimetre of
muscle tissue were calculated. The number of cells
positive for staining for receptors was tested for a pos-
sible correlation with the expression of pDC marker
BDCA-2/CD303 and MX-1 protein in consecutive ser-
ial sections, expressed as the percentage of positively
stained area per total tissue section (Table 2). A
Table 1 Clinical characteristics and autoantibody profiles of patients at time of muscle biopsya and results of immunohistochemical analysis of biopsies
Patient Dg Years
since Dg












BAFF-R BCMA TACIb CD19 CD138 TACI/
vesselb
1 Def PM −0.8 + − − − 0 No ILD, A, R 3 + + − + + +
2 Def PM 0 + − − RNP-70 0 No ILD 0 - − + − − +
3 Def PM 0.4 + − − Ku-72 0.3 Yes ILD, A, R, MH, SS 0 NA − − NA NA −
4 Def PM 1.6 + − − − 1.6 Yes ILD, E, T 2 − − − − + +
5 Prob PM 2.9 + − − − 2.8 Yes ILD 3 + + + − + +
6 Prob DM 22.5 + + + La, Ku-86 28.5 Yes ILD, R, SR 2 − + − − − −
7 Prob PM 6.5 − + + La 6.4 Yes A, pSS 3 + + + + + +
8 Def IBM 0.5 − + + La 0.4 Yes pSS 3 + + + − + +
9 Def PM 0.2 − + − − 0.2 Yes ILD, R 2 − − − NA NA +
10 Def IBM* 0 − + − − 13.7 Yes R 2 − − + NA NA +
11 Def DM 8.8 − − − Mi-2, PM-Scl 9.0 Yes SR, SS 2 − − − − + +
12 Def PM 0.8 − − − − 0.5 Yes 0 − − − − − −
13 Prob PM −0.1 − − − − 0 No 2 − − − − + +
14 Prob DM 0 − − − − 0 No SR 0 − − − − − +
15 Def PM 5.0 − − − − 4.9 Yes 2 − − + − + −
16 Def IBM 0.8 − − − Histones 0.8 Yes E 2 − + − − + +
17 Def IBM* 0 − − − − 9.0 Yes R 1 + − − − + +
18 Def DM 0.3 − − − − 0.3 Yes SR 1 − − − NA NA +
19 Prob DM 0.1 − − − − 0.2 Yes SR 2 − + − NA NA +
20 Def IBM 8.4 − − − − 8.4 Yes 0 − − − NA NA +
21 Def PM 9.4 − − − − 9.7 Yes A 0 − − − NA NA +
22 Def DM 13.2 − − − Ku-86 13.2 Yes SR 1 − − − − − −
23 Prob IBM* −1.1 − − − − 2.1 Yes 0 − − + NA NA +
aA, Arthritis; BAFF-R, B-cell-activating factor of the tumour necrosis factor family receptor; BCMA, B-cell maturation antigen; Def, Definitive; Dg, Diagnosis; DM, Dermatomyositis; E, oesophagus; IBM, Inclusion body
myositis; ILD, Interstitial lung disease; MH, Mechanic’s hands; NA, Not assessed; PM, Polymyositis; Prob, Probable; pSS, Primary Sjögren’s syndrome; R, Raynaud’s phenomenon; SR, Skin rash; SS, Sjögren’s syndrome;
T, Thrombosis; TACI, Transmembrane activator and calcium modulator and cyclophilin ligand interactor. bTACI was also expressed in vessels (*) at time of biopsy diagnosed as PM, (**) score: 0=no infiltrate; 1=scattered
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expression was performed by computerised image ana-
lysis on the total tissue area using the Leica QWin soft-
ware and microscope (DM RXA2; Leica, Wetzlar,
Germany). There was a high degree of correlation be-
tween the results of conventional microscopic evalu-
ation and those of computerised image analysis of
BDCA-2-positive cells and of total MX-1 expression, as
previously reported [23].Immunofluorescent staining and confocal microscopy
Muscle tissue sections were fixed in 2% formaldehyde
PBS and washed in PBS. Saponin 0.1% PBS solution was
used for permeabilisation, blocking solutions and wash-
ing. Serum blocking was performed with 4% normal hu-
man serum (NHS) and 6% animal serum (same species
as secondary antibody). A kit was used for avidin-biotin
blocking (Vector Laboratories). Antibodies were diluted
in PBS-saponin with 1% NHS.
Sections were stained overnight at 4°C with primary anti-
bodies towards receptors for BAFF (1:400 dilution) as de-
scribed above and with goat polyclonal antibodies to CD19
(1:400 dilution; Santa Cruz Biotechnology, Inc, Dallas,
Texas, USA) or anti-CD138 (1:400 dilution; R&D Systems
Europe, Abingdon, UK). Samples were incubated for 1 hour
with secondary biotinylated horse anti-mouse IgG anti-
bodies (1:300 dilution; Vector Laboratories) and donkey
anti-goat polyclonal antibodies (1:300 dilution, Alexa Fluor
594 conjugate; Life Technologies, Carlsbad, CA, USA),
followed by incubation with streptavidin-Alexa Fluor 488
conjugate (1:300 dilution; Molecular Probes, Eugene, OR,
USA). 4′,6-diamidino-2-phenylindole was used to visualise
the nuclei. The Leica QWin software and microscope were
used to detect the immunofluorescent staining and for
confocal microscopy.Table 2 Correlations between expression of receptors for BAF
I IFN production and plasmacytoid dendritic cells in muscle t
BAFF-Rb BCMAb









aBAFF-R, B-cell-activating factor of the tumour necrosis factor family receptor; BCMA
Interferon α/β–inducible myxovirus resistance 1 protein; TACI, Transmembrane activ
correlation analysis were: bNumbers of positive cells counted by conventional micro
receptors. cQuantitative evaluation of expression by computerised image analysis (p
Spearman´s rank order test. ***P <0.005, **P <0.01, *P <0.05, †P <0.1.Statistical analyses
Data were analysed using GraphPad Prism statistical
software (version 5.02; GraphPad Software, La Jolla, CA,
USA). For analysis of differences between groups, a
Kruskal-Wallis with Dunn’s post hoc test and a nonpara-
metric Mann-Whitney U test were performed. Spearman’s
rank-order test was used for correlations of parameters. A
P-value ≤0.05 was considered statistically significant.
Data are presented as median and range from minimum
to maximum or mean ± SD based on distribution.
Results
Clinical, laboratory and serologic findings
Ten patients were positive and thirteen patients were
negative for anti-Jo-1 or anti-Ro52/anti-Ro60 autoanti-
bodies and constituted the two groups whose muscle tissue
was analysed. Detailed autoantibody profiles are presented
in Table 1.
BAFF-R, BCMA and TACI expression in muscle tissue
Mononuclear cell infiltrates were present in 16 of 23 pa-
tient samples (Table 1). In 11 of them, one or more re-
ceptors for BAFF were expressed. BAFF-R, BCMA and
TACI expression was present in five, seven and seven of
the eleven positive samples. In addition, scattered TACI-
positive cells were seen in biopsies from two patients
without infiltrates. BAFF-R positivity (median, 1.8 cells/
mm2 (minimum 0.5 to maximum 55.0)) was seen in
clusters of infiltrating mononuclear cells, which included
CD19-positive B cells (Figures 1A and 1B, Additional
file 2: Figures S2A and S2B). The receptors BCMA (3.2
cells/mm2 (0.14 to 11.2)) and TACI (1.5 cells/mm2 (0.3 to
16.6)) were observed both in mononuclear inflammatory
cell infiltrates (Figures 1C and 1D, Additional file 3: Figure
S3A) and within the muscle tissue in scattered cells with
plasma cell–like morphology. Blood vessels expressingF and expression of markers for B and plasma cells, type
issuea
TACIb CD19b CD138b





, B-cell maturation antigen; BDCA-2, Blood dendritic cell antigen 2; MX-1,
ator and calcium modulator and cyclophilin ligand interactor. Data included to
scopy per area (n/mm2). Included samples which expressed at least one of the









Figure 1 (See legend on next page.)
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Figure 1 Serial sections of muscle tissue mononuclear cell infiltrate. These sections were taken from a representative anti-Ro52/anti-Ro60-
positive patient with polymyositis. They are immunohistochemically stained for B-cell marker CD19 (A) and plasma cell marker CD138 (E). Original
magnification, ×25. Details of infiltrate (original magnification, 1.25 × 25) stained for B cell–activating factor of the tumour necrosis factor family
receptor (BAFF-R) (B), B cell maturation antigen (BCMA) (C), transmembrane activator and calcium modulator and cyclophilin ligand interactor
(TACI) (D), interferon α/β–inducible myxovirus resistance 1 (MX-1) protein (F) and plasmacytoid dendritic cell marker blood dendritic cell antigen
2 (BDCA-2) (G) compared to immunoglobulin G1 isotype control (H). Brown colour indicates positively stained cells, indicated by arrows.
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present in 18 patients (Table 1) and 5 healthy individuals.
Occasional TACI-positive cells were recorded in three of
the healthy control biopsies, but BAFF-R and BCMA
staining was negative in all controls.
Taken together, all three receptors were expressed in
cells located in inflammatory infiltrates. Of the five tissue
samples with expression of BAFF-R in inflammatory infil-
trates, BCMA was expressed in four and TACI in three.
The number of cells per square millimetre expressing
BAFF-R correlated with the number of cells per square
millimetre expressing BCMA (n = 8, rS = 0.76, P = 0.02).
Of the seven BCMA-positive samples, three were also
positive for TACI.
The three receptors were distributed into different
sublocalisations of the infiltrates. BAFF-R- and BCMA-
expressing cells were localised in separate clusters
within infiltrates (Figures 1B and 1C), whereas TACI was
expressed mainly by scattered mononuclear cells of
plasma cell–like morphology and in areas positive for
plasma cell marker CD138 in the endomysium (Additional
file 3: Figures S3A and S3B). Within infiltrates, BAFF-R
expression was observed in two patients in large clusters
of cells, many of which were CD19-positive (up to 100
cells) (Additional file 2: Figure S2B), whereas BCMA was
present in other and smaller clusters (approximately 10
cells) (Figure 1C) and TACI was weakly positive in scat-
tered cells within infiltrates (Figure 1D).B cells and plasma cells in muscle tissue and
colocalisation with BAFF receptors and with plasmacytoid
dendritic cell markers
Consecutive sections of muscle biopsies from 15 patients
were available for staining of B cell and plasma cell
markers. Plasma cells (CD138-positive) were detected in
10 patients (4.7 cells/mm2 (1.1 to 161.7)) within cellular
infiltrates (Figure 1E) or as scattered cells in endomysial
and/or perivascular areas. Accumulations of CD19-
positive B cells were observed in only two patients (7.1
and 9.1 cells/mm2), both in large mononuclear infil-
trates (Figure 1A, Additional file 2: Figure S2A).
The expression pattern in serial sections suggests that
CD138-positive plasma cells colocalised with the distri-
bution of BCMA-positive cells (Figures 1C and 1E) andthat some plasma cells also expressed TACI, albeit
weakly (Figures 1D and 1E, Additional file 3: Figures
S3A and S3B). BAFF-R positivity was seen in cells in the
same areas as CD19-positive B cells in consecutive sec-
tions (Figures 1A and 1B, Additional file 2: Figures S2A
and S2B). The number of CD138-expressing cells corre-
lated positively with the number of BCMA-expressing
cells (rS = 0.79, P = 0.001) and also with BAFF-R (rS =
0.70, P = 0.006) (Table 2). Colocalisation of CD138
and BCMA was confirmed by confocal microscopy with
CD138/BCMA double-positive cells in serial consecutive
sections, within infiltrates (Figures 2A and 2B) and as
scattered infiltrating cells within muscle tissue.
BAFF-R- and CD138-positive cells were distributed in
different sublocalisations of tissue infiltrates. Therefore,
double-staining for these two markers was not done. In
both patients with CD19-positive B cells, the CD19/
BAFF-R double-positive clusters were present within
mononuclear infiltrates (Figure 2C and Additional file 2:
Figures S2C and S2D). In two other samples (Table 1,
patients 5 and 8), several BAFF-R single-positive cells
were detected by light and immunofluorescence micros-
copy. The number of CD19-expressing cells weakly cor-
related with expression of BAFF-R (rS = 0.49, P = 0.05)
and BCMA (rS = 0.44, P = 0.08) (Table 2).
In the same areas of infiltrates with CD138-positive
plasma cell expression, we found cells positively stained
for MX-1 protein (Figure 1F) and BDCA-2 (that is,
pDCs) (Figure 1G and Additional file 3: Figure S3D).
The percentage area of BDCA-2-positive pDCs, as esti-
mated by computerised image analysis, correlated with
the number of cells expressing CD138 (rS = 0.54, P =
0.04) (Table 2) and weakly with BCMA (rS = 0.42, P =
0.06) (Table 2, Figure 3) [23]. In addition, there was a
weak correlation between number of TACI-positive cells
and MX-1-positive cells (rS = 0.38, P = 0.08) (Table 2).
BAFF-R, BCMA and TACI expression in muscle tissue in
relation to autoantibody profile and clinical manifestations
The number of BAFF-R- and BCMA-expressing cells per
area was higher in biopsies from patients with anti-Jo-1
and/or anti-Ro52/anti-Ro60 autoantibodies compared to
patients without these autoantibodies and to healthy con-
trols (P = 0.007 and P = 0.03, respectively, by Kruskal-












Figure 2 Immunofluorescent double-staining of B and plasma cells expressing receptors for B cell–activating factor of the tumour
necrosis factor family in the muscle mononuclear cell infiltrate from a representative anti-Ro52/anti-60-positive patient with
polymyositis. Immunofluorescence staining for plasma cell marker CD138 (red) and B cell maturation antigen (BCMA) (green) (A) in a tissue
biopsy section from the same patient as in Figure 1 (original magnification, ×200) with details (B) of staining for CD138, BCMA, 4′,6-diamidino-2-
phenylindole (DAPI) and an overlay created with the confocal microscope (original magnification, ×600). Scattered CD19-positive cells were also
present remote from the CD138-positive cells and were positive for BAFF-R (C) as expressed in details of CD19 (red), BAFF-R (green), DAPI (blue)
and an overlay created with the confocal microscope (original magnification, ×600).
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ences in expression of BAFF-R, BCMA and TACI when
we compared patients with versus without anti-Jo-1 or
anti-Ro52/anti-Ro60 autoantibodies (P = 0.01, 0.047 and
0.03, respectively) (Figure 3).
No significant differences in expression of BAFF-Rs or
the presence of B cells or plasma cells in muscle tissue
were recorded with respect to PM, DM or IBM subdiag-
noses. There were no associations between BAFF-Rs or
B and plasma cell markers and disease or treatment dur-
ation, or with treatment at time of biopsy (Table 1).Discussion
A major finding in our study is the expression of recep-
tors for BAFF in mononuclear cells in muscle tissue of
patients with myositis. The presence of the receptors
was associated with detectable plasma cells, as well as
with the presence of anti-Jo-1 and anti-Ro52/anti-Ro60
autoantibodies in sera. In addition, there was a correl-
ation between number of cells expressing receptors for
BAFF, number of plasma cells and expression of markers
of pDCs. These data are suggestive of local BAFF-driven



















































































Figure 3 Quantitative assessment of the expression of
receptors for B cell–activating factor of the tumour necrosis
factor family in muscle tissues. Cells positive for B cell–activating
factor of the tumour necrosis factor family receptor (BAFF-R) (A),
B cell maturation antigen (BCMA) (B) or transmembrane activator
and calcium modulator and cyclophilin ligand interactor (TACI) (C)
per square millimetre of muscle tissue area are shown for healthy
controls and patients with myositis with or without anti-Jo-1 and/or
anti-Ro52/anti-Ro60 autoantibodies. IBM, Inclusion body myositis.
Data presented are P-values calculated by Kruskal-Wallis (KW) test
and Mann-Whitney (MW) U test. Horizontal bars represent medians
for each group.
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tive for anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.
Our data, in addition to the already described beneficial
effects of B lymphocyte depletion by rituximab (anti-
CD20) in refractory PM or DM [27,33-35], including pa-
tients with antisynthetase syndrome [27,33], support a role
for local autoreactive B lymphocytes in these conditions.
A correlation between serum levels of anti-Jo-1 autoanti-
bodies and disease activity in patients with myositis has
been described [36], but it is not known where the anti-
Jo-1 autoantibodies are produced. The target antigen for
anti-Jo-1 autoantibodies—histidyl tRNA synthetase—is
ubiquitously expressed, but, interestingly, with higher ex-
pression in epithelial cells of lungs compared to other
healthy organs, and also in higher extent in regenerating
muscle fibres than in differentiated fibres [37]. There-
fore, a local autoantigen presentation in muscle tissue
could be considered.
In our patients, we saw only modest numbers of
CD19-positive B cells in muscle tissue, whereas the pres-
ence of CD138-positive plasma cells was more promin-
ent. This may imply that B cells continue to differentiate
in this environment, which is supported by the beautiful
sequence analysis by Salajegheh et al. [10]. Also, in other
studies, researchers have demonstrated this unusual bias
for plasma cells [9,11]. A similar low level expression of
CD19 on long-lived plasma cell precursors has been de-
scribed in peripheral blood from patients with primary
Sjögren’s syndrome, rheumatoid arthritis and active sys-
temic lupus erythematosus [38-40], and downregulation
of CD19 expression during differentiation into antibody-
secreting cells has been documented [41,42]. It is tempting
to speculate that, similarly to the kidneys of patients with
lupus nephritis, affected muscles of patients with IIM
could provide a survival niche for autoantibody-producing
plasma cells [43,44]. Our hypothesis is that the maturation
of plasma cells and possible affinity maturation within
muscle tissue of patients with myositis could be driven by
the autoantigen in muscle tissue under the permissive
cytokine environment (Figure 4).
In another study, which included patients with derm-
atomyositis, a significant increase in mRNA levels of
Figure 4 Schematic illustration of suggested interaction of dendritic cells, type I interferon and local B cell differentiation in myositis
muscle. Plasmacytoid dendritic cells (pDCs) stimulated by immunocomplexes produce type I interferon (IFN-α/β) and induce conventional
dendritic cells (DCs) to secrete the cytokines B cell–activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand
(APRIL), which influence B cell differentiation and survival. Their three receptors—BAFF receptor (BAFF-R), B cell maturation antigen (BCMA) and
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)—are differentially expressed during the maturation of
B cells from naïve to memory B cells and plasma cell generation. Class switch, differentiation to plasmablast and survival are also enhanced by
IFN-α/β. The presence of APRIL in myositis muscle is unclear, but its importance for immunoglobulin (Ig) class switch is known.
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compared to normal controls [28]. Using a polyclonal
anti-BAFF-R antibody, the authors described strong stain-
ing of BAFF-R on some inflammatory cells. However, they
also found BAFF and BAFF-R on regenerating and nec-
rotic muscle fibres, but not in normal muscle. We could
not confirm the staining for BAFF-R in regenerative or
necrotic fibres, because the BAFF-R expression was lim-
ited to inflammatory cells. The discrepancy between the
staining patterns in these two studies can probably be
explained by different specificities of antibodies used for
staining, whereas monoclonal antibodies, as used in our
study, usually are more specific. Furthermore, the staining
pattern was validated on tonsil tissue (Additional file 1:
Figure S1), where we observed BAFF-R positivity in areaspositive for CD19 cells with patterns similar to those de-
scribed for expression in tonsillar [15] and reactive lymph-
oid [45] tissues.
The number of cells expressing BAFF-R, BCMA or
TACI was significantly higher in patients with anti-Jo-1
and anti-Ro52/anti-Ro60 autoantibodies compared to pa-
tients without these autoantibodies. Moreover, the recep-
tors were localised to areas with B cells and plasma cells
on serial sections. The double-positivity of receptors and
B cells or plasma cells, as suspected on the basis of the
distribution of cells expressing BAFF-R or BCMA, was
confirmed by immunofluorescent staining and confocal
microscopy. This is consistent with the known differential
expression of receptors for BAFF during the development
of B cells into Ig-producing plasma cells [14,15].
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positively with expression of BAFF-R. This was a statis-
tical correlation, but the cells were present in separate
areas within the infiltrates. The correlation between
BAFF-R and CD138 may reflect the presence of acti-
vated BAFF-R-positive T cells, supporting a differenti-
ation of B cells into plasma cells in addition to the
BAFF/APRIL and IFN signals. This remains to be proven
because the staining for T cell markers was outside the
scope of this study.
Two or more receptors for BAFF appeared together
in several tissue samples, but they were distributed into
different sublocalisations of the infiltrates or in scattered
cells. The numerical correlation between the number of cells
expressing BAFF-R and the number of BCMA-positive
cells could be explained by the presence of B cells in vari-
ous differentiation stages in individual tissues.
The finding of plasma cells in areas with plasmacytoid
DC markers, together with the receptor BCMA on serial
sections and the trend for quantitative correlations be-
tween these markers, suggests a local role for pDCs in
inducing differentiation of autoantibody-producing cells
in muscle tissue. This is further supported by the presence
of MX-1 in areas with plasmacytoid DCs and plasma cell
markers. The pDCs represent a local source of type I IFN
and have previously been described in inflamed myositis
muscle tissue [23,24]. Excitingly, B cells can enhance IFNα
production by pDCs [46], which in turn could locally
stimulate myeloid DCs (shown in PM and IBM muscle
[47]) to produce BAFF (as reviewed previously [48]).
Plasma cell survival and antibody secretion are known to
be enhanced by BAFF [49], and local affinity maturation
of B lymphocytes and plasma cells in muscle tissue of pa-
tients with myositis has been reported [9-11]. During B
cell differentiation to plasma cells, BAFF-R expression is
downregulated and BCMA is upregulated, which results
in differential local expression of these receptors in muscle
tissue infiltrates. The possible role of locally produced type
I IFN is also consistent with our previous findings of a
negative correlation between serum levels of IFN-α with
muscle involvement as assessed by magnetic resonance
imaging [50].
There are some limitations of this study. One is the
weak staining for TACI. Therefore, we may have underes-
timated the TACI expression. However, the TACI staining
was distinct from the negative isotype control, and the
concentration of the antibody was chosen with respect to
background staining in muscle fibres. We could see ex-
pression of TACI in scattered cells of patient samples
without infiltrates and also in three control tissues. This
could be related to TACI staining of vessels, which has
also been reported in other tissues [51]. This uncertainty
could modify the correlation between TACI-positive cells
and cells expressing CD138 and BDCA-2, which wasweak. Expression of TACI on DCs has been demonstrated
on in vitro monocyte-derived DCs [52]. Indeed, we
observed TACI expression in BDCA-2-positive areas
(Figure 2 and Additional file 3: Figure S3). The limita-
tion of the availability of muscle tissue explains why we
had samples available for detecting B cell markers from
only 15 of the 23 patients.
There were some patients with anti-Jo-1 or anti-Ro52/
anti-Ro60 autoantibodies without BAFF-R expression in
muscle tissue. Importantly, these patients did not have
detectable inflammatory cell infiltrates in either the first
or last section of a series, which reflects the patchy nature
of the inflammatory infiltrates often observed in muscle
biopsies from patients with myositis.
Conclusions
Our data indicate a possible local role for BAFF in muscle
tissue from patients with myositis, particularly in a subset
of patients with anti-Jo-1 or anti-Ro52/anti-Ro60 auto-
antibodies. The presence of receptors for BAFF in the
vicinity of, and even colocalised with, B cells and plasma
cells further substantiates the possibility that local auto-
antibody production could occur in the muscle and might
be induced by type I IFN produced by pDCs. BAFF may
thus be a potential target for treatment in this subset of
patients with myositis.
Additional files
Additional file 1: Figure S1. Immunohistochemistry staining for plasma
cell marker (CD138), B-cell marker (CD19) in human tonsil. Serial sections
stained for receptors for BAFF (BCMA, TACI and BAFF-R). Brown colour
indicates positively stained cells. BAFF-R is present in the areas with B
cells, while BCMA and TACI were expressed in the plasma cell (CD138)
positive areas. Upper left panel shows staining with IgG1 isotype control
(original magnification, ×25; detail magnification, 1.25 × 25).
Additional file 2: Figure S2. Immunohistochemistry staining for B cell
marker CD19 (A) and BAFF-R (B) in an infiltrate of muscle tissue from
representative anti-Jo-1-positive patient with polymyositis. Brown colour
indicates positively stained cells (original magnification, ×250). The weak
expression of CD19 could reflect the differentiation of B cells into the
pre-plasma cells. Double-positivity for B cell marker CD19 and BAFF-R
(C) seen by fluorescent microscopy (original magnification × 200), with
details of staining for CD19 (red), BAFF-R (green), DAPI (blue) and overlay
(D) from confocal microscope (original magnification, ×600).
Additional file 3: Figure S3. Immunohistochemistry staining for TACI
(A), plasma cell marker CD138 (B), isotype control (C) and a marker of
plasmacytoid dendritic cell BDCA-2 (D) in an endomysial infiltrate of
patient with polymyositis. Brown colour indicates positively stained cells
(original magnification, ×250). Details of staining for CD138 (red), TACI
(green), DAPI (blue), overlay (E) and enlargement of double positivity for
plasma cell marker CD138 and TACI (F) seen by confocal microscope
(original magnification, ×600).
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